Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) FCF Margin (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of FCF Margin data on record, last reported at 289.25% in Q3 2025.

  • For Q3 2025, FCF Margin rose 15264.0% year-over-year to 289.25%; the TTM value through Sep 2025 reached 25.39%, up 53036.0%, while the annual FY2024 figure was 238.15%, 70357.0% up from the prior year.
  • FCF Margin reached 289.25% in Q3 2025 per STOK's latest filing, down from 183.26% in the prior quarter.
  • Across five years, FCF Margin topped out at 1073.0% in Q1 2022 and bottomed at 897.18% in Q2 2023.
  • Average FCF Margin over 4 years is 363.88%, with a median of 441.89% recorded in 2024.
  • Peak YoY movement for FCF Margin: crashed -149810bps in 2023, then skyrocketed 66587bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 675.89% in 2022, then decreased by -10bps to 745.11% in 2023, then surged by 86bps to 103.41% in 2024, then crashed by -180bps to 289.25% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 289.25% in Q3 2025, 183.26% in Q2 2025, and 83.04% in Q1 2025.